tbuckley/cabot-search huggingface dataset:
Evaluation of the adoption, acceptance, and satisfaction of SurvivorLink as a communication tool for pediatric cancer survivors.
Authors: Ann Mertens, Rebecca Williamson, Jordan Gilleland-Marchak, Lillian R. Meacham, Brooke Cherven, Paula Edwards
Journal: Journal of Clinical Oncology (2016)

89 Background: With the number of cancer survivors growing, focus on early recognition and treatment of late effects is even more imperative for life-long survivorship care. Electronic personal health records (PHR) potentially offer self-management and e-learning support which can empower the survivor, as well be used as a communication tool with healthcare providers (HCP). Methods: We developed a PHR, SurvivorLink (www.cancersurvivorlink.org), as a patient-centered tool to support pediatric cancer survivors, increase knowledge of late effects and survivor care, and promote communication between patients/parents and providers. Measures of success for a sustainable PHR implementation include adoption/use, acceptance, satisfaction and usability. The objectives of this feasibility study are to determine characteristics that predict the success of this PHR tool. An online pre-/post survey was administered to young adult survivors and parents of child survivors who registered on SurvivorLink. Results: Overall, 155 parents and 93 survivors completed the pre-test survey; 75% and 86% respectively have subsequently logged into SurvivorLink after initial registration. Individuals who used this PHR were more likely to be survivors (vs. parents; Odds Ratio (OR): 2.2, 95% CI: 1.1, 4.2). Other demographic variables were analyzed but no significant differences were found between users and non-users. Among users not aware of their need for specialized survivor care at the pre-survey, 52% reported awareness of the need for survivor care in the post-survey (vs 0% of non-users). Parents/survivors also reported high acceptance: 90% would use in the future, 82% stated it would help with advocating for survivor's health; and usability: 96% would recommend to other survivors/parents, 95% would recommend to their healthcare provider. Conclusions: SurvivorLink can improve knowledge around the importance of survivor care, and is both adopted and accepted by survivors/ parents independent of demographic differences. Research is underway to establish SurvivorLink's effectiveness as an advocacy/communication tool for survivor/parent with HCP in the self-management of their healthcare.
Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2.
Authors: Francesco Piazza, Sabrina Manni, Carmela Gurrieri, Anna Colpo, Laura Quotti Tubi, Anna Cabrelle, Livio Trentin, Gianpietro Semenzato
Journal: Blood (2009)
Perioperative evaluation of medical comorbidities at a comprehensive cancer center.
Authors: Sunil Kumar Sahai, Divya K. Nekkalapudi, Jessica T. Foreman, Heather Y. Lin, Rachel Voss, Tayab A. Andrabi, Thomas A. Aloia, Jessica Hwang
Journal: Journal of Clinical Oncology (2016)

e271 Background: The Internal Medicine Perioperative Assessment Center (IMPAC), the first and only dedicated perioperative cancer medicine service at a comprehensive cancer center, provides medical risk assessment and optimization of patients undergoing surgery at The University of Texas MD Anderson Cancer Center. We examined the demographic and clinical characteristics of patients seen in the IMPAC program over the last decade. Methods: Retrospective cohort study of patients who were referred to the IMPAC program from November 2004 through January 2015. We identified patient demographics as well as type of cancer at presentation and frequency of comorbidities. Our analysis was based on review of billing data using institutional administrative and clinical databases. Comorbidities were determined based on ICD-9 billing diagnosis at time of initial consultation in the IMPAC program. Results: During the study period, 29,732 patients between the ages of 9 to 105 years old were evaluated for perioperative risk assessment, and 50% were female. The patients were referred to IMPAC program from a primary cancer center. The top referring centers were Head &amp; Neck (7353 patients), Gastrointestinal (4939), Genitourinary (4759), Breast (3565), Gynecology (3175), Melanoma/Skin (1355), Leukemia/Lymphoma (1056), Sarcoma (975), Endocrine (913), Thoracic (779), and Brain and Spine (714). The most frequent comorbidities among all patients seen in the IMPAC program were hypertension (57%), dyslipidemia (35%), diabetes (22%), and coronary artery disease and heart failure (16%). Conclusions: Cardiovascular diseases and diabetes were common comorbidities among patients with cancer awaiting surgery. The identification and optimization of comorbid medical conditions such as diabetes and cardiovascular disease are important because they are known to predict clinical outcomes. Future work should focus on optimal perioperative management strategies to reduce risk of complications in patient with cancer and comorbidities.
Comparative Performance of the Euroline Allergy and Immunocap Systems in the Measurement of Specific IgEs to Common Foods and Aeroallergens Among Thai Children
Authors: Sonthila Hongvilai, Jittima Veskitkul, Wanwipa Chaimongkol, Punchama Pacharn, Orathai Jirapongsananuruk, Nualanong Visitsunthorn, Pakit Vichyanond
Journal: Journal of Allergy and Clinical Immunology (2017)
Applying Academic Detailing and Process Change to Promote Choosing Wisely
Authors: Dennis H. Novack, Pamela Duke, Daniel B. Wolfson
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal.
Authors: Marwan Fakih, Bert H. O'Neil, E. Gabriela Chiorean, Howard S. Hochster, Emily Chan, David J. Mauro, Cathy Eng
Journal: Journal of Clinical Oncology (2016)

TPS786 Background: ADXS11-001 is a live attenuated Listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy bioengineered to secrete an antigen-adjuvant fusion protein (fused to HPV16 E7) that has demonstrated promising single-agent activity in human papilloma virus-driven cancers (e.g., head and neck, cervical) and promising clinical activity in combination with chemoradiation in high-risk squamous cell carcinoma (SCC) of the anorectal canal. This study will assess the efficacy and safety of ADXS11-001 monotherapy in patients with persistent/recurrent, locoregional or metastatic anorectal SCC. Methods: Phase 2, multicenter, open-label, 2-stage trial (NCT02399813). Eligible patients (female or male; ≥ 18 years) will have histologically confirmed, measurable (defined by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1) anorectal SCC, previously have received ≥ 1 line of therapy for metastatic/locally advanced disease, Eastern Cooperative Oncology Group performance status of 0 or 1 with adequate organ function. Patients will receive intravenous ADXS11-001 (1×10 9 colony-forming units) every 3 weeks during a 9-week treatment cycle for ≤ 2 years or until a discontinuation criterion is met (eg documented progression, unacceptable adverse events [AEs], noncompliance with study procedures or treatments). Tumor assessments will occur every 9 weeks. AEs will be monitored throughout the study and will be graded according to the National Cancer Institute-Common Toxicity Criteria version 4.0. The study will be conducted in a 2-stage design. Stage 1 will evaluate the safety and efficacy of ADXS11-001 in 31 patients. If the efficacy from Stage 1 has a response rate (RR) ≥ 10% by RECIST 1.1 or 6-month progression free survival (PFS) ≥ 25%, enrollment will proceed to Stage 2 with the addition of another 24 evaluable patients. RR and PFS will be described for the overall population. The end of the study will be defined as 1 year after the last patient has been enrolled. To date, enrollment has begun at 1 study site. Clinical trial information: NCT02399813.
Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer
Authors: M.R. Chica-Parrado, A. Santonja, A. Lluch-Hernandez, J. Albanell, A. Sanchez-Muñoz, I. Chacón, L. Calvo, P. Sanchez-Rovira, J.l.a. De Haba, L. Vicioso, M. Martin, A. Plazaola, A. Prat, N. Ribelles, M. Sánchez-Aragó, J.M. Jerez, M.J. Escudero, R. Caballero, E. Carrasco, E. Alba Conejo
Journal: Annals of Oncology (2016)
RTHP-13. SECONDARY MALIGNANCY RATES AND ADVERSE RADIATION EFFECTS AFTER STEREOTACTIC RADIOSURGERY FOR BENIGN ACOUSTIC NEUROMA: AN INSTITUTIONAL EXPERIENCE
Authors: Heva Saadatmand, Tavish Nanda, Pranav Nanda, Cheng-Chia Wu, Jeraldine Lesser, Simon Cheng, Muhammad Afghan, Steven Isaacson, Sameer Sheth, Tony Wang, Michael Sisti
Journal: Neuro-Oncology (2016)

Data on the risk for de novo secondary neoplasms after gamma knife radiosurgery (GKRS) is limited to case reports and anecdotal experience. No studies have determined actual rates from long-term follow-up. This study reviewed acoustic neuroma (AN) patients with greater than 3-year follow-up (range: 3.1-14.7 years) to assess secondary neoplasm and other adverse effects due to GKRS in our cohort. 419 patients received GKRS for AN between 1998-2015 (137 with follow-up >3 years, 81 with >5 years, and 22 with >10 years). Secondary neoplasm was categorized by three levels of radiographic/clinical suspicion: L1, low radiographic suspicion with possibility of residual/recurrent neuroma or simple post-treatment change; L2, high radiographic suspicion with possibility of residual/recurrent neuroma or simple post-treatment change; L3: biopsy-proven secondary neoplasm after high radiographic suspicion. Two patients were L1 at 7.9 and 6.6 years. Two patients were L2 at 3.99 years (parotid gland mass) and 10.3 years (petrous bone schwannoma), both at the peripheral margin of GKRS treatment. One patient was L3 with biopsy-proven subependymoma in the region of GKRS 4.7 years post-treatment. Other effects possibly attributed to GKRS included one case of labyrinthitis/semicircular obliteration at 14.6 years, optic neuropathy at 11.2 years, osteoid necrosis at 8.1 years, and trigeminal neuralgia at 4.7 years. Including L2-L3 patients, 2.2% of patients may develop a secondary neoplasm due to GKRS after 3-year follow-up. 2.9% may develop adverse effects. No secondary neoplasms found in our cohort were malignant, and most were slow-growing, benign neoplasms posing little neurologic threat. Our data suggest that patients may be re-assured that any post-treatment de novo neoplasms are likely to be benign. Our findings are consistent with estimated secondary malignancy rates of .01 to .1% at ten years.
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray.
Authors: Giuseppe Visani, Alessandro Isidori, Maria Rosaria Sapienza, Simona Righi, Antonella Laginestra, Claudio Agostinelli, Elena Sabattini, Michele De Nictolis, Massimo Valentini, Meris Donati, Roberto Emiliani, Anna Gazzola, Claudia Mannu, Maura Rossi, Francesco Alesiani, Giovanni Martinelli, Ilaria Iacobucci, Stefania Paolini, Stefano Ascani, Carlo Finelli, Nicola Vianelli, Stefano A. Pileri, Pier Paolo Piccaluga
Journal: Blood (2009)
LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
Authors: Y.S. Yap, L-M. Tseng, K.L. Blackwell, D. Cameron, S. Foo, V. Sriuranpong, C-S. Huang, T-Y. Chao, T-Y. Kim, S-C. Chen, K.H. Jung, K.S. Lee, J-H. Sohn, J.H. Kim, M-F. Hou, Y. Han, F. Souami, S. Dhuria, M. Miller, S. Verma
Journal: Annals of Oncology (2016)
Association of body mass index with survival outcome in three breast cancer subtypes.
Authors: Takeo Fujii, Takahiro Kogawa, Caimiao Wei, Tamer Mahmoud Fouad, Kenichi Harano, Young Sam Park, Bora Lim, Debu Tripathy, Naoto T. Ueno, Jennifer Keating Litton
Journal: Journal of Clinical Oncology (2015)

1580 Background: High body mass index (BMI) is a poor prognostic indicator in breast cancer patients. However, data are still limited about the association between baseline BMI and survival according to breast cancer subtype. We evaluated the relationship between BMI and survival among breast cancer receptor subtypes (hormone receptor positive (HR), HER 2 positive (HER), and triple-negative breast cancer (TNBC). Methods: This study included 4069 patients with stages I, II, or III breast cancer diagnosed between 1990 to April 30, 2013 who had received neoadjuvant systemic therapy and subsequent definitive surgery collected from Breast Medical Oncology database under IRB-approved protocol. Baseline clinical information including BMI (kg/m2) was collected, and patient characteristics were tabulated. HR is defined as either estrogen or progesterone receptor positive (positive by immunohistochemistry (IHC) or > 10% staining) with negative HER2 receptor, and HER2 is defined as HER2 positive (IHC 3+ or HER2/CEP17 ratio ≥ 2.0) regardless of their hormone receptor status. Correlation between BMI as a continuous variable and survival was analyzed by using univariable and multivariable Cox proportional hazard models. Results: Median follow-up for survivors was 37 months. Baseline characteristics are shown in Table. A univariable analysis showed a trend towards unfavorable overall survival in TNBC patients whose BMIs were 27.2-40.4. In multivariable analysis, BMI was a significant predictor of poor overall survival only in the HR (hazard ratio 1.017; 95%CI 1-1.033, adjusted p = 0.046). Conclusions: Our large cohort analysis demonstrated that higher BMI was significantly associated with poor survival only in HR, suggesting that baseline BMI might be a prognostic indicator only for the least aggressive subtype, HR. HR (n = 2054) HER2 (n = 1075) TNBC (n = 940) BMI, median (range) 27.6 (15.5-66) 27.5 (15.9-67.6) 28.5 (14.3-61.7) Recurrence-free survival at 5 years (95%CI) 77.8 (75.5-79.9) 76.4 (73.1-79.3) 63.2 (59.5-66.8) Overall survival at 5 years (95%CI) 83.4 (81.2-85.3) 82.8 (79.6-85.5) 67.2 (63.3-70.8)
Responsible e-Prescribing Needs e-Discontinuation
Authors: Shira Fischer, Adam Rose
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NIMG-04. CLINICAL IMPLICATION OF HIGH B-VALUE DWI FOR PREOPERATIVE DIFFERENTIATION OF GLIOBLASTOMA FROM ITS DIFFERENTIALS
Authors: Manish Kolakshyapati, Rupendra Bahadur Adhikari, Takeshi Takayasu, Ryo Nosaka, Vishwa Jeet Amatya, Yukio Takeshima, Yuji Akiyama, Kazuhiko Sugiyama, Kaoru Kurisu, Fumiyuki Yamasaki
Journal: Neuro-Oncology (2016)

Study of quantitative radiological data (radiomics) is widely used for diagnostic purpose, however, their use for tumor differentiation is still limited. The purpose of this study is to evaluate the diagnostic value of high b-value DWI for differentiation of glioblastoma from malignant lymphomas and metastatic brain tumors. Preoperative MRIs including DWI (b=1000 and 4000 s/mm2) of patients with newly diagnosed malignant tumor admitted in our institution were analyzed retrospectively after approval of institutional review board. Histologically confirmed 64 patients of glioblastoma, 32 of malignant lymphoma and 46 of brain metastases were included. Presence of non-enhancing peritumoral DWI high lesion (NePDHL) was confirmed in both DWI sequences. Gray-matter lesions were excluded. Lesions were termed “Definite” (D-NePDHL) if present within 3cm of the enhanced tumor as high-intensity with signal-intensity ratio (SIR) of ≥30% as compared to contralateral normal white matter in both sequences. Discriminant analysis between histological diagnosis and presence of D-NePDHL was done. Kaplan-Meier survival analysis incorporating existence of D-NePDHL was performed. DWI SIR of ≥30% in both sequences enabled differentiation between definite and probable DWI high signal intensity lesions. In 25% of glioblastoma patients D-NePDHL was present while it was conspicuously absent in malignant lymphoma and metastatic brain tumors. Specificity and positive predictive value were 100%. Cases with D-NePDHL had significantly early local (p=0.0467) and distant/dissemination recurrence (p<0.0001) and carried poor prognosis (p=0.0007). Use of high b-value (b-4000) DWI is advantageous in clinical setting. Presence of D-NePDHL is very specific for glioblastoma and indicates poor prognosis. D-NePDHL is a significant indicator for early local and distant/dissemination recurrence in glioblastoma. Study of peritumoral DWI and high b-value DWI is beneficial for tumor differentiation and for prognosis.
Central nervous system involvement in non-Hodgkin’s lymphoma: A single-center analysis of prognostic factors for survival
Authors: A. Korfel, K. Jahnke, P. Martus, S. Schwartz, L. Fischer, H. Stein, E. Thiel
Journal: Journal of Clinical Oncology (2005)

6718 Background: The prognosis of patients with non-Hodgkin’s lymphoma (NHL) and central nervous system (CNS) involvement is generally regarded as poor. Very little is known about prognostic factors in these patients. The aim of this retrospective single-center study was to analyze the clinical characteristics and outcome of NHL patients with CNS involvement and identify prognostic factors for survival. Methods: We searched our hospital records for NHL patients with CNS involvement diagnosed from 1982 to 2003, and 43 were identified. Prognostic factors for survival were assessed by univariate and multivariate analysis. Results: The median age at CNS manifestation was 61 (range, 22–87); the median Karnofsky performance status was 55 (range 10–90). Thirty-five patients had CNS relapse and 8 patients CNS involvement at first presentation. Isolated CNS disease was found in 6 patients and concomitant systemic disease in 36. Initial management included systemic chemotherapy (n=25), chemo-/radiotherapy (n=16), dexamethasone (n=1), and no treatment (n=1). Chemotherapy consisted of CNS-penetrating drugs (high-dose methotrexate or ifosfamide) in 24 patients. Intrathecal chemotherapy was given to 34 patients. Twenty-six patients showed a CNS response. The median survival from the time of CNS manifestation and the median overall survival (OAS) were 5.5 (0–82.5+) and 37 (0–181) months, respectively. Lactate dehydrogenase (LDH) at CNS manifestation (p = .051) and CNS response to therapy were identified as independent prognostic factors for survival on multivariate analysis (p = <.001), whereas age at initial diagnosis, initial CNS involvement, initial LDH, and treatment with CNS-penetrating chemotherapy for CNS involvement were only significant on univariate analysis. All but one of 9 patients who are still alive received substances able to sufficiently penetrate the blood-brain barrier. All survivors were disease-free at the last follow-up. Conclusions: Long-term survival can be achieved in patients with NHL and CNS involvement. LDH at CNS manifestation and CNS response to therapy were significantly associated with survival. No significant financial relationships to disclose.
Translational Medicine in HIV-1 Infection: Preclinical and Clinical Development of the Green Tea Catechin, Epigallocatechin Gallate, as Therapy and Immunological Signatures
Authors: Christina L. Nance, Rosa Yeh, Mary Paul, Filiz O. Seeborg, Thomas Giordano, Roberto Arduino, Rustin Crutchley, Melinda Mata, Evelyn Leechawengwongs, William T. Shearer
Journal: Journal of Allergy and Clinical Immunology (2017)